Eledon (ELDN) President Steven Perrin Receives Retention Award

What Happened
Steven Perrin, President and a director of Eledon Pharmaceuticals (ELDN), received 152,353 shares on July 31, 2026 as the settlement of a retention bonus award (awarded at $0.00). To satisfy tax-withholding obligations on the settlement date, 72,138 of those shares were withheld/disposed at $3.38 per share, producing withholding proceeds of $243,826. Net impact: Perrin acquired 80,215 shares (152,353 awarded minus 72,138 withheld).

Key Details

• Transaction date: July 31, 2026. Filing date (Form 4): August 4, 2026. (Form 4s are generally due within 2 business days of the transaction.)
• Award: 152,353 shares issued at $0.00 (code A — grant/award).
• Tax withholding: 72,138 shares withheld/disposed at $3.38 each for $243,826 (code F — tax withholding).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes: F1 — shares issued on settlement of a retention bonus agreement entered April 27, 2023. F2 — shares withheld to pay tax withholding obligations on the settlement date.
• Transaction codes: A = award/grant; F = tax withholding (routine).

Context
This was a settlement of a previously agreed retention bonus, not an open-market purchase or sale driven by trading decisions. The withholding of shares to cover taxes is a common, administrative step and does not by itself indicate a broader buy/sell signal.